These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 36420633

  • 1. Effects of solriamfetol on on-the-road driving in participants with narcolepsy: A randomised crossover trial.
    Vinckenbosch F, Lammers GJ, Overeem S, Chen D, Wang G, Carter LP, Zhou K, Ramaekers JG, Vermeeren A.
    Hum Psychopharmacol; 2023 Jan; 38(1):e2858. PubMed ID: 36420633
    [Abstract] [Full Text] [Related]

  • 2. Effects of solriamfetol on on-the-road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea.
    Vinckenbosch F, Asin J, de Vries N, Vonk PE, Donjacour CEHM, Lammers GJ, Overeem S, Janssen H, Wang G, Chen D, Carter LP, Zhou K, Vermeeren A, Ramaekers JG.
    Hum Psychopharmacol; 2022 Nov; 37(6):e2845. PubMed ID: 35633275
    [Abstract] [Full Text] [Related]

  • 3. Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.
    Dauvilliers Y, Shapiro C, Mayer G, Lammers GJ, Emsellem H, Plazzi G, Chen D, Carter LP, Lee L, Black J, Thorpy MJ.
    CNS Drugs; 2020 Jul; 34(7):773-784. PubMed ID: 32588401
    [Abstract] [Full Text] [Related]

  • 4. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy.
    Emsellem HA, Thorpy MJ, Lammers GJ, Shapiro CM, Mayer G, Plazzi G, Chen D, Carter LP, Villa KF, Lee L, Menno D, Black J, Dauvilliers Y.
    Sleep Med; 2020 Mar; 67():128-136. PubMed ID: 31926465
    [Abstract] [Full Text] [Related]

  • 5. A randomized study of solriamfetol for excessive sleepiness in narcolepsy.
    Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, Chen D, Carter LP, Wang H, Lu Y, Black J, Dauvilliers Y.
    Ann Neurol; 2019 Mar; 85(3):359-370. PubMed ID: 30694576
    [Abstract] [Full Text] [Related]

  • 6. Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions.
    Devine JK, Schwartz L, Hursh S, Asin J, de Vries N, Vonk PE, Vermeeren A, Donjacour CEHM, Vinckenbosch F, Ramaekers JG, Janssen H, Wang G, Chen D, Carter LP, Overeem S, Lammers GJ.
    Neurol Ther; 2023 Feb; 12(1):249-265. PubMed ID: 36494591
    [Abstract] [Full Text] [Related]

  • 7. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea.
    Malhotra A, Shapiro C, Pepin JL, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo PJ, Mayer G, Sarmiento K, Baladi M, Chandler P, Lee L, Schwab R.
    Sleep; 2020 Feb 13; 43(2):. PubMed ID: 31691827
    [Abstract] [Full Text] [Related]

  • 8. Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy.
    Rosenberg R, Thorpy MJ, Dauvilliers Y, Schweitzer PK, Zammit G, Gotfried M, Bujanover S, Scheckner B, Malhotra A.
    J Clin Sleep Med; 2022 Jan 01; 18(1):235-244. PubMed ID: 34283019
    [Abstract] [Full Text] [Related]

  • 9. A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants.
    Zomorodi K, Chen D, Lee L, Swearingen D, Carter LP.
    Clin Pharmacol Drug Dev; 2021 Apr 01; 10(4):404-413. PubMed ID: 32935460
    [Abstract] [Full Text] [Related]

  • 10. Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
    Weaver TE, Pepin JL, Schwab R, Shapiro C, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo PJ, Mayer G, Sarmiento K, Baladi M, Bron M, Chandler P, Lee L, Malhotra A.
    J Clin Sleep Med; 2021 Oct 01; 17(10):1995-2007. PubMed ID: 34606437
    [Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor.
    Carter LP, Henningfield JE, Wang YG, Lu Y, Kelsh D, Vince B, Sellers E.
    J Psychopharmacol; 2018 Dec 01; 32(12):1351-1361. PubMed ID: 30269642
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials.
    Subedi R, Singh R, Thakur RK, K C B, Jha D, Ray BK.
    Sleep Med; 2020 Nov 01; 75():510-521. PubMed ID: 33032062
    [Abstract] [Full Text] [Related]

  • 13. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial.
    Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Lu Y, Black J, Malhotra A, Strohl KP, TONES 3 Study Investigators.
    Am J Respir Crit Care Med; 2019 Jun 01; 199(11):1421-1431. PubMed ID: 30521757
    [Abstract] [Full Text] [Related]

  • 14. The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study.
    van de Loo AJAE, Bervoets AC, Mooren L, Bouwmeester NH, Garssen J, Zuiker R, van Amerongen G, van Gerven J, Singh J, der Ark PV, Fedgchin M, Morrison R, Wajs E, Verster JC.
    Psychopharmacology (Berl); 2017 Nov 01; 234(21):3175-3183. PubMed ID: 28755104
    [Abstract] [Full Text] [Related]

  • 15. Solriamfetol: A Review in Excessive Daytime Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnoea.
    Hoy SM.
    CNS Drugs; 2023 Nov 01; 37(11):1009-1020. PubMed ID: 37847434
    [Abstract] [Full Text] [Related]

  • 16. Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy.
    Yang J, Gao J.
    Expert Rev Clin Pharmacol; 2019 Aug 01; 12(8):723-728. PubMed ID: 31215815
    [Abstract] [Full Text] [Related]

  • 17. Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea.
    Rosenberg R, Baladi M, Bron M.
    J Clin Sleep Med; 2021 Apr 01; 17(4):711-717. PubMed ID: 33226332
    [Abstract] [Full Text] [Related]

  • 18. On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers.
    Vermeeren A, Sun H, Vuurman EF, Jongen S, Van Leeuwen CJ, Van Oers AC, Palcza J, Li X, Laethem T, Heirman I, Bautmans A, Troyer MD, Wrishko R, McCrea J.
    Sleep; 2015 Nov 01; 38(11):1803-13. PubMed ID: 26039969
    [Abstract] [Full Text] [Related]

  • 19. On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.
    Vermeeren A, Vets E, Vuurman EF, Van Oers AC, Jongen S, Laethem T, Heirman I, Bautmans A, Palcza J, Li X, Troyer MD, Wrishko R, McCrea J, Sun H.
    Psychopharmacology (Berl); 2016 Sep 01; 233(18):3341-51. PubMed ID: 27424295
    [Abstract] [Full Text] [Related]

  • 20. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
    Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG.
    JAMA; 2020 Dec 01; 324(21):2177-2186. PubMed ID: 33258890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.